{"id":"W2807732548","doi":"10.1111/dom.13413","title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","year":2018,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Dapagliflozin; Medicine; Placebo; Renal function; Kidney disease; Type 2 diabetes; Internal medicine; Urology; Clinical endpoint; Adverse effect; Randomization; Diabetes mellitus; Gastroenterology; Randomized controlled trial; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183169,0.0006190629,0.002428496,0.0002193322,0.0002206535,0.0006932476,0.0004090669,0.0007242917,0.002245638],"category_scores_gemma":[0.002895137,0.0002640875,0.001795297,0.0003182316,0.0003579757,0.0004929462,0.0005249602,0.001251735,0.0003819451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003394037,"about_ca_system_score_gemma":0.0004274289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003197159,"about_ca_topic_score_gemma":0.000795996,"domain_scores_codex":[0.9990722,0.0005479401,0.00005492211,0.0001071907,0.0001655377,0.00005214287],"domain_scores_gemma":[0.9991258,0.0003189442,0.0002343363,0.00008657661,0.00007852029,0.0001559931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8336923,0.01030081,0.03863831,0.001203765,0.007190348,0.0001442568,0.0001306906,0.001606135,0.006567184,0.0003586544,0.00411777,0.09604982],"study_design_scores_gemma":[0.6305483,0.168537,0.172883,0.0002345349,0.009899941,0.000544171,0.00009626914,0.005126485,0.002842228,0.0007349452,0.008443979,0.0001090727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98602,0.008276371,0.0004974082,0.000492193,0.00009789775,0.0004396692,0.001379456,0.00003516922,0.002761715],"genre_scores_gemma":[0.993763,0.002403772,0.0005185799,0.0006977976,0.0002766949,0.0003148164,0.001166998,0.000009713067,0.0008485804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002428496,"threshold_uncertainty_score":0.01154584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005970261016607593,"score_gpt":0.2181164105582141,"score_spread":0.2121461495416065,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}